The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
Source: CNBC
Saturday, 21. December 2024
Share:
20. December 2024 22:40
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
